Free Case Evaluation
You will never be charged a fee unless a recovery is made for you.
Tepezza (teprotumumab) lawsuits are being filed by people who received the drug infusion to treat thyroid eye disease (TED) and suffered hearing loss or tinnitus (ringing in the ears) as a result of the Tepezza treatment.
The Tepezza lawsuits claim that Horizon Pharmaceuticals Inc. failed to alert regulators and the public that Tepezza could cause hearing loss and tinnitus.
If you are considering filing a Tepezza lawsuit, call us at 800-796-1636 or submit your case details online and someone will contact you shortly. You pay nothing unless your lawsuit is successful and you receive compensation.
At Trustwell Law, our experienced attorneys take a personalized, compassionate approach. We cut through the legalese and partner with our clients. We have access to the expertise, resources, and manpower to fully investigate each case and fight for and with our clients to get the justice they deserve.
In January 2020, the U.S. Food and Drug Administration (FDA) approved Tepezza, Horizon Therapeutics’ treatment for thyroid eye disease (TED), under the Fast Track and Breakthrough Therapy Designation. The FDA also gave Tepezza an Orphan Drug designation because TED was considered a rare disease for which other treatments were not readily available.
Thyroid eye disease is an autoimmune disease that involves inflammation of the eye muscles and fatty tissue behind the eye. Symptoms of TED include dry, red, bulging, or watery eyes; double vision; difficulty closing the eyes; and vision problems. TED is primarily associated with an overactive thyroid gland due to Graves’ disease.
In just the few years since 2020 when Tepezza became the first and only FDA-approved treatment for thyroid eye disease, numerous studies have found that hearing loss and tinnitus are associated with its use. Examples include:
If you or a loved one have been diagnosed with hearing loss or tinnitus after receiving treatment with Tepezza, contact us to discuss filing a Tepezza lawsuit. You may be entitled to compensation for past and future medical expenses, pain and suffering, lost wages, and possible punitive damages.
The consultation is free, and if we take your case, you pay us nothing unless you receive compensation.
Article Sources
Belinsky, I., et al. (2022, January-February). Teprotumumab and Hearing Loss: Case Series and Proposal for Audiologic Monitoring. Retrieved from https://pubmed.ncbi.nlm.nih.gov/34085994/
Campbell, P. (2021, March 26). Teprotumumab Linked to Hearing Loss, Tinnitus in New Study. Retrieved from https://www.endocrinologynetwork.com/view/teprotumumab-tepezza-linked-to-hearing-loss-tinnitus-in-new-study
Chow, A., and R. Silkiss. (2022, April 13). Teprotumumab-associated chronic hearing loss screening and proposed treatments. Retrieved from https://pubmed.ncbi.nlm.nih.gov/35418378/
Endocrine Society. (2021, March 20). Increased risk of hearing impairment with new thyroid eye disease treatment. Retrieved from https://www.endocrine.org/news-and-advocacy/news-room/featured-science-from-endo-2021/increased-risk-of-hearing-impairment-with-new-thyroid-eye-disease-treatment
Endocrine Society. (2022, January 24). Thyroid Eye Disease. Retrieved from https://www.endocrine.org/patient-engagement/endocrine-library/thyroid-eye-disease
Horizon Therapeutics. (2022, February 15). New Post-Marketing Safety Analysis Shows Rate of Hearing-Related Events Associated with TEPEZZA (teprotumumab-trbw) Comparable with Clinical Trial Observations. Retrieved from https://ir.horizontherapeutics.com/news-releases/news-release-details/new-post-marketing-safety-analysis-shows-rate-hearing-related
Horizon Therapeutics. (2021, October). Tepezza Prescribing Information. Retrieved from https://www.hzndocs.com/TEPEZZA-Prescribing-Information.pdf
Kahaly, G., et al. (2021, June). Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials. Retrieved from https://pubmed.ncbi.nlm.nih.gov/33865501/
Kossler, A., C. M. Sears, and C. Dosiou. (2021, May 3). Hearing Loss and Teprotumumab. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8089925/
Mayo Clinic. (2019, February 8). Tinnitus. Retrieved from https://www.mayoclinic.org/diseases-conditions/tinnitus/symptoms-causes/syc-20350156
Sears, C., et al. (2022, August). Hearing Dysfunction After Treatment With Teprotumumab for Thyroid Eye Disease. Retrieved from https://pubmed.ncbi.nlm.nih.gov/35227694/
Weibel v. Horizon Pharmaceuticals, Inc. (2022, October 25). Horizon Therapeutics USA, Inc’s Motion to Dismiss Plaintiff’s Complaint. Retrieved from https://www.aboutlawsuits.com/wp-content/uploads/2022-10-25-Motion.pdf
Weibel v. Horizon Pharmaceuticals, Inc. (2022, August 25). Complaint. Retrieved from https://www.johnsonbecker.com/wp-content/uploads/Tepezza-Hearing-Loss-Lawsuit-Weibel-1.pdf
Yu, C., et al. (2021, December). Audiology findings in patients with teprotumumab associated otologic symptoms. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8452766/
You will never be charged a fee unless a recovery is made for you.